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Abstract 
Objectives. While previous studies have identified type 2 diabetes (T2D) as a risk factor for 
colorectal cancer (CRC), little is known about whether T2D influences participation in CRC 
screening programmes. This study tested the extent to which Type 2 Diabetes is negatively 
associated with colorectal cancer screening uptake.    
Methods. In this study, we analysed individual data of screening-eligible men and women 
aged 60 to 75 without cancer diagnosis from wave 6 of the English Longitudinal Study of 
Ageing (collected 2012-2013) to investigate whether T2D influences CRC screening 
behaviour independently of demographic characteristics, body mass index, socio-economic 
status, and other chronic diseases.  
Results. Using both self-reported T2D diagnosis and glycated haemoglobin (HbA1c), 
individuals who reported to have been diagnosed with T2D or had HbA1c levels of 48 
mmol/mol or higher were less likely to have ever completed a screening test (faecal occult 
blood test; 62.8% vs 75.8%, p<0.01) or to be up-to-date with their biennial screening 
invitation (60.2% vs 72.0%, p<0.05). The negative associations of T2D on CRC screening 
were found both in unadjusted and adjusted regression models.  
Conclusions. Future qualitative and quantitative research should identify reasons for this 
discrepancy to inform interventions to increase screening uptake in this high-risk population. 
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Introduction 
Individuals with type 2 diabetes (T2D) are at higher risk of developing cancer, including 
kidney cancer, non-small-cell lung, pancreas, early gastric, breast, ovarian and colorectal 
cancer (CRC) [1-7] potentially due to insulin resistance and compensatory hyperinsulinemia 
[8].  
As the number of T2D patients worldwide has consistently increased [9] and CRC is among 
the most frequently diagnosed cancers [10], it is important to investigate the role of T2D in 
CRC preventive behaviours such as CRC screening uptake. Individuals with T2D are at 
higher CRC risk, and therefore regular participation in CRC screening programmes is 
particularly recommended [11]. So far, studies have shown that women with T2D are less 
likely to undergo cervical screening [12-15] and breast cancer screening [13,14, 16], although 
support for this has not been completely consistent [12].   
Findings for CRC screening are equivocal. Two US studies, looking at samples of women 
aged 40 or older, demonstrated that those with T2D were more likely to be screened for CRC 
than those without [12,17].  Similarly, a recent US study looking at men and women aged 50 
or older showed that those with T2D were more likely to be up-to-date with the 
recommended CRC screening [18]. In contrast, another US study, of older women 
years), found a negative association [15]. All of the aforementioned studies were based in the 
US and looked at opportunistic rather than organised CRC screening programmes. 
The only non-US study of is an English prospective survey of 55-year olds intending to have 
flexible sigmoidoscopy screening [19]. The study found an independent negative association 
between reporting T2D and screening attendance. However, the study was limited to people 
who had already expressed an intention to attend. Currently, there is a lack of studies looking 
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at the association for men and women in the context of an organised population-based CRC 
screening programme.   
To address this limitation, the current study used data from the English Longitudinal Study of 
Ageing (ELSA; a nationally representative study of community-dwelling English adults aged 
\Hars that started in 2002-2003 (wave 1) [20]) to examine the role of T2D in CRC 
screening in a screening-eligible sample of English adults aged 60 to 75 years. In England, 
the National Health Service (NHS) invites people in that age range to complete a home-based 
stool test (faecal occult blood test; FOBt) every two years. We tested the hypothesis that 
people who reported having been diagnosed with diabetes or had elevated HbA1c levels at 
wave 6 are less likely to have ever been screened and less likely to be up to date with CRC 
screening.  
Methods 
Study population 
We used individual data of screening-eligible men and women aged 60 to 75 without cancer 
diagnosis IURP(/6$¶VZDYHTXHVWLRQQDLUHDQGQXUVHYLVLWZKLFKZDVFROOHFWHGin 2012 
and 2013. All participants gave informed consent at each wave of data collection. ELSA was 
approved by the London Multicentre Research Ethics Committee (MREC/01/2/91), and 
informed consent was obtained from all participants.  All study methods were performed in 
accordance with the Helsinki Declaration and good clinical and scientific practice.  
Screening uptake 
Ever screening was measured from the individual questionnaire in wave 6 RI(/6$µHave 
you ever completed the NHS bowel cancer screening test using the home test kit?¶ZLWK
response options being µyes¶ or µno¶. Individuals who reported to have completed the 
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screening test were then asked to indicate the date of their most recent bowel cancer 
screening test. The response to this follow-up question was used to determine whether 
individuals followed the recommended biennial screening interval. Out of the 5160 
participants in the screening-eligible age range of 60 to 75 without cancer diagnosis, 4925 
(95.4%) responded to the date of the screening question. 
Type 2 diabetes 
T2D was measured using WKHTXHVWLRQµ+DVDGRFWRUHYHUWROG\RX that you have diabetes or 
KLJKEORRGVXJDU"¶IURPWKHLndividual wave 6 questionnaire and from the glycated 
haemoglobin (HbA1c) level measured in the blood sample taken by the nurse during the 
wave 6 nurse visit. HbA1c values, ranging from 15-137 mmol/mol were dichotomised into 
two categories; those below 48 mmol/mol and those with values of 48 mmol/mol or higher 
[21]. The question about having a diabetes diagnosis was answered by 4882 participants in 
the eligible age range, while blood samples were obtained from 3270 participants. For the 
purpose of this study, we only considered respondents who answered the self-reported 
question and had a blood sample result recorded. Individuals were classified as having 
diabetes if they either reported a diabetes diagnosis or had an HbA1c value of 48 mmol/mol 
or higher.  
  
Body Mass Index (BMI) and other comorbidities 
Objective BMI measurements (height in m2/weight in kg) were taken from the wave 6 nurse 
visit and categorised into normal weight (BMI<25), overweight (BMI 25±29.9), class I 
obesity (BMI 30±34.9), class II obesity (BMI 35±39.9) and class III obesity (BMI>=40) [22].  
Assessments of coronary heart diseases, such as angina or myocardial infarction, depression, 
respiratory diseases like asthma and lung disease and stroke were based on the questions from 
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WKHLQGLYLGXDOTXHVWLRQQDLUHVµ:KDWW\SHRIHPRWLRQDOQHUYRXVRUSV\FKLDWULFSUREOHPVGR
\RXKDYH"¶ DQG³+DVDGRFWRUHYHUWROG\RXWKDW\RXKDYHDQ\RIWKHFRQGLWLRQVRQWKLVFDUG"¶ 
Covariates 
We included gender, age, living arrangement, education and household non-pension wealth 
as socio-demographic covariates from the individual questionnaire. Living arrangement was 
coded as in binary as either living alone or with somebody.  
Education was assessed in 4 categories UDQJLQJIURP ³QRIRUPDOHGXFDWLRQ´WR 
³XQLYHUVLW\GHJUHHRUKLJKHU´  
Non-pension wealth is an indicator of socio-economic status (SES) in older people [23]. Non-
pension wealth was measured at the family level, and this is the sum of net primary housing 
wealth, net physical wealth (other property wealth, business wealth and other physical assets) 
and net financial wealth. It included saving accounts, ISAs, TESSAs, premium bonds, 
national savings, PEPs, shares, trusts, bonds, other savings minus credit card, private and 
other debt. Quintiles of non-pension wealth (1 = low, 5 = high) were used for the analysis 
[24]. 
Statistical analysis 
Characteristics of the sample were described using mean scores (standard deviations) for 
continuous variables and numbers (percentages) for categorical variables. We used 
unadjusted and adjusted multivariate logistic regression models to investigate whether T2D 
was associated with CRC screening behaviour.  
The adjusted model controlled for demographic characteristics, BMI, SES, chronic heart 
disease, depression, respiratory problems and stroke.  Note that we do not adjust for ethnicity, 
as the vast majority (97.2%) of the analytic sample reported a white ethnic background. All 
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statistical analyses were conducted with Stata/SE version 15.1 (StataCorp LP, College 
Station, TX).  
Results 
Descriptive characteristics 
The analytic sample comprised of 3270 participants. The characteristics of the sample are 
presented in Table 1. The mean age of the participants was 66.7 years, and the majority fell 
into the overweight and obesity categories. 422 participants (12.9%) were classified as having 
T2D. Most of them reported a diabetes diagnosis and had an elevated HbA1c level of 48 
mmol/mol or higher (N=235; 55.7%). 104 (24.6%) of the diabetic group (N= 422) who did 
not report a diagnosis were classified as having T2D because of their HbA1c level. Finally, 
83 (19.7%) self-reported a diagnosis but had an HbA1c level below 48 mmol/mol. 
Using the alternative classification of diabetes, 108 were classified as having undiagnosed 
diabetes, while 83 were classified as diabetes patients who control their diabetes well and 235 
who control their diabetes poorly. 
Ever uptake of CRC screening 
Table 2 shows that individuals were less likely to have ever done CRC screening if they had 
T2D in both the unadjusted and the adjusted regression models (62.8% vs 75.8%,Odds Ratio 
(OR) 0.54, 95% confidence interval (CI) 0.43-0.67, p<0.01 and adjusted Odds Ratio (aOR) 
0.70, 95% CI 0.56-0.89, p<0.01, see Table 3 for full results of the  univariate and 
multivariate analysis).  Class III obesity and increasing age were negatively associated with 
self-reported ever uptakes. Reporting a coronary heart disease or respiratory disease were 
also negatively associated with CRC screening in the unadjusted but not the adjusted 
regression. In contrast, women and participants who were cohabiting, respondents with 
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formal education and from a higher income group were more likely to have done the stool 
test.  
Being up-to-date with CRC screening  
T2D was also negatively associated with being up-to-date with the recommended CRC 
screening interval in both the unadjusted and adjusted regression models (60.2% vs 72.0%, 
OR 0.59, 95% CI 0.48-0.73, p<0.01 and aOR 0.74, 95% CI 0.59-0.94, p<0.05).  
Similarly, to the results for ever uptake, age and Class III obesity were negatively associated 
with being up-to-date with CRC screening. While diagnosis of chronic heart diseases and 
respiratory diseases were again negatively associated with CRC screening in the unadjusted 
regressions, only the association for respiratory diseases remained statistically significant in 
the fully adjusted model. In contrast, relative affluence, being female, and having A-levels or 
a university degree were positively associated with screening. 
  
Discussion 
In this study, diabetes was negatively associated with CRC screening behaviour, 
independently whether it was defined by self-reported diabetes alone or in combination with 
HbA1c. Individuals with diabetes were less likely to have ever done CRC or be up-to-date 
with their biennial CRC screening invitation. These findings are particularly concerning as 
people with diabetes are at a moderately increased risk of developing CRC [24].  
In line with a recent US study looking at individuals with diabetes which found that those 
who had an HbA1c level of 48 mmol/mol or higher were less likely to have been screened for 
CRC [25]. The present study adds to the literature by looking at the link between diabetes and 
CRC screening behaviour in an organised population-based CRC programme with routine 
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call and recall. Previous research has focused on the US [12, 15, 17, 18], while the one 
previous study of men and women in the UK included only those who had already expressed 
an intention to attend flexible sigmoidoscopy screening, limiting the generalisability of the 
findings to the population at large [19]. 
Nevertheless, the results of this earlier UK based study [19] are in keeping with the present 
analysis whereby those with diabetes were less likely to report being up to date with the 
recommended biennial screenings. Our study findings are also consistent with studies 
showing lower cervical [12-15] and breast-screening uptake [13, 14, 16] in people with 
diabetes. Given that the association we found was independent of several potential 
confounders, particularly the level of obesity, SES, and other comorbidities, indicates that 
there is a need to explore the diabetes specific barriers to screening.  
Diabetes treatment guidelines highlight the importance of engaging in positive health 
behaviours [26] and attending CRC and other population-based cancer screenings are a part 
of engaging in proactive behaviours to benefit one's long-term health.  Awareness of a 
chronic condition such as T2D could be considered a trigger for positive lifestyle change 
[27]. However, the findings of this study support research suggesting lower levels of 
engagement with positive health behaviour may be habitual in this population and difficult to 
modify [28]. Furthermore, there could be a common underlying mechanism in how 
individuals engage in unhealthy lifestyle leading to increased risk of diabetes, cancer or other 
chronic conditions [29]. These mechanisms could extend to the perceived susceptibility of 
subsequent associated risks and cues to action (e.g. CRC screening) [30, 31].  Low SES could 
exert a strong influence on these complex mediating pathways via low literacy, healthcare 
access, healthy food options etc. and our results for education and wealth seem to support this 
mechanism. A recent study, using the ELSA cohort, demonstrated that limited positive 
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behaviour change appears to occur following the diagnosis of T2D, with no changes in 
physical activity, fruit and vegetable intake and alcohol consumption detected [32].  
Furthermore, a recent conceptual framework describing the potential influence of 
comorbidities on the timely diagnosis of cancer described mechanisms through which 
comorbid conditions could either facilitate help seeking and screening, or be associated with 
delays [34]. In the case of cancer screening, individuals with diabetes might have competing 
demands, as the management of diabetes can take priority (for both patients and healthcare 
providers) and this might interfere with participating in screening [34, 35].   
The competing demands mechanism has been reported to interfere with help-seeking for 
symptomatic patients with serious comorbidities [36]. It can be even more relevant in the 
context of screening, where individuals are not experiencing cancer symptoms and instead 
have other more urgent healthcare needs.   
Our study had several limitations. First, we used self-reported measures for CRC screening 
participation and comorbidities which may be subject to recall bias. However, a recent study 
that compared self-reported CRC screening behaviour with participation recorded by the 
programme found that more than 90% were able to accurately report whether they had ever 
completed a FOB test [33].  Secondly, this cross-sectional study does not look at the date of 
diabetes diagnosis, making the direction of the association between diabetes and CRC 
screening unclear.  
In conclusion, we found evidence that people with T2D are less likely to undergo CRC 
screening in England. Further research is required to understand how to motivate and 
facilitate CRC screening in this and other groups at moderately increased CRC risk. 
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Table 1. Participant characteristics (N=3270) 
 N (%) 
Age (Mean and SD) 66.7 4.5 
Gender   
Male 1500 (45.9%) 
Female 1770 (54.1%) 
Living arrangement   
Alone 832 (25.4%) 
With somebody 2438 (74.6%) 
Education   
No formal education 733 (22.4%) 
Foreign or other 392 (12.0%) 
A-levels or equivalent 1641 (50.2%) 
University degree 504 (15.4%) 
Non-pension wealth category   
5 (Most affluent) 716 (21.9%) 
4 678 (20.7%) 
3 670 (20.5%) 
2 645 (19.7%) 
1 (least affluent)  561 (17.2%) 
BMI categories   
Normal weight (<25) 906 (27.7%) 
Overweight (25-29.9) 1381 (42.2%) 
Class I obesity (30-34.9) 681 (20.8%) 
Class II obesity (35-39.9) 231 (7.1%) 
Class II obesity (>40) 71 (2.2%) 
Coronary heart diseases  
No 3040 (93.0%) 
Yes 230 (7.0%) 
Depression   
No 3047 (93.2%) 
Yes 223 (6.8%) 
Respiratory diseases   
No 2807 (85.8%) 
Yes 463 (14.2%) 
Stroke  
No 3171 (97.0%) 
Yes 99 (3.0%) 
Diabetes   
No 2848 (87.1%) 
Yes 422 (12.9%) 
BMI= body mass index; HbA1c= glycated haemoglobin; SD standard deviation 
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Table 2. Screening uptake according to demographics (N=3270) 
 Ever uptake of CRC screening Being up-to-date with CRC screening 
 No Yes (% Yes) p-value* No Yes (% Yes) p-value* 
Overall uptake 846 2424 (74.1)  966 2304 (70.5%)  
         
Gender         
Male 423 1077 (71.8%) 0.005 464 1036 (69.1%) 0.108 Female 423 1347 (76.1%) 502 1268 (71.6%) 
Living arrangement         
Alone 276 556 (66.8%) 
<0.001 320 512 (61.5%) <0.001 With somebody 570 1868 (76.6%) 646 1792 (73.5%) 
Education         
No formal education 267 466 (63.6%) 
<0.001 
296 437 (59.6%) 
<0.001 Foreign or other 88 304 (77.6%) 108 284 (72.5%) A-levels or equivalent 385 1256 (76.5%) 436 1205 (73.4%) 
University degree 106 398 (79.0%) 126 378 (75.0%) 
Non-pension wealth category        
5 (Most affluent) 120 596 (83.2%) 
<0.001 
143 573 (80.0%) 
<0.001 
4 137 541 (79.8%) 163 515 (76.0%) 
3 190 480 (71.6%) 216 454 (67.8%) 
2 210 435 (67.4%) 236 409 (63.4%) 
1 (least affluent)  189 372 (66.3%) 208 353 (62.9%) 
BMI categories         
Normal weight (<25) 233 673 (74.3%) 
<0.001 
277 629 (69.4%) 
<0.001 
Overweight (25-29.9) 310 1071 (77.6%) 365 1016 (73.6%) 
Class I obesity (30-34.9) 197 484 (71.1%) 211 470 (69.0%) 
Class II obesity (35-39.9) 73 158 (68.4%) 79 152 (65.8%) 
Class II obesity (>40) 33 38 (53.5%) 34 37 (52.1%) 
Coronary heart diseases       
No 771 2269 (74.6%) 0.016 884 2156 (70.9%) 0.035 Yes 75 155 (67.4%) 82 148 (64.4%) 
Depression         
No 792 2255 (74.0%) 0.558 898 2149 (70.5%) 0.747 Yes 54 169 (75.8%) 68 155 (69.5%) 
Respiratory diseases         
No 703 2104 (75.0%) 0.008 796 2011 (71.6%) <0.001 Yes 143 320 (69.1%) 170 293 (63.3%) 
Stroke       
No 818 2353 (74.2%) 0.578 933 2238 (70.6%) 0.401 Yes 28 71 (71.7%) 33 66 (66.7%) 
Diabetes         
No 689 2159 (75.8%) 
<0.001 798 2050 (72.0%) <0.001 Yes 157 265 (62.8%) 168 254 (60.2%) 
BMI= body mass index; HbA1c= glycated haemoglobin; SD standard deviation 
*p-value refers to Chi-square test 
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Table 3. Predictors of CRC screening 
 Ever uptake of CRC screening Being up-to-date with CRC screening 
  Unadjusted model Adjusted model  Unadjusted model Adjusted model 
Variable (%) OR 95% CI OR 95% CI (%) OR 95% CI OR 95% CI 
Overall uptake (74.1%)     (70.5%)     
Age 0.934 0.918 - 0.951** 0.942 0.924 - 0.960**  0.919 0.903 - 0.935** 0.926 0.909 - 0.943** 
Gender           
Male (71.8%) Ref.  Ref.  (69.1%) Ref.  Ref.  
Female (76.1%) 1.251 1.069 - 1.463** 1.471 1.243 - 1.741** (71.6%) 1.131 0.973 - 1.315 1.341 1.140 - 1.577** 
Living arrangement           
Alone (66.8%) Ref.  Ref.  (61.5%) Ref.  Ref.  
With somebody (76.6%) 1.627 1.370 ± 1.932** 1.514 1.132 - 2.027** (73.5%) 1.734 1.468 ± 2.047** 1.338 1.014 - 1.765* 
Education           
No formal education (63.6%) Ref.  Ref.  (59.6%) Ref.  Ref.  
Foreign or other (77.6%) 1.979 1.495 - 2.621** 1.514 1.132 - 2.027** (72.5%) 1.781 1.365 ± 2.324** 1.338 1.014 - 1.765* 
A-levels or equivalent (76.5%) 1.869 1.548 ± 2.258** 1.427 1.164 - 1.748** (73.4%) 1.872 1.558 ± 2.250** 1.408 1.155 - 1.715** 
University degree (79.0%) 2.151 1.656 - 2.795** 1.666 1.264 - 2.196** (75.0%) 2.032 1.583 - 2.609** 1.558 1.196 - 2.030** 
Non-pension wealth category          
5 (Most affluent) (83.2%) Ref.  Ref.  (80.0%) Ref.  Ref.  
4 (79.8%) 0.795 0.606 - 1.043 0.873 0.662 - 1.153 (76.0%) 0.788 0.612 - 1.017 0.869 0.669 - 1.128 
3 (71.6%) 0.509 0.393 - 0.659** 0.602 0.461 - 0.787** (67.8%) 0.525 0.411 - 0.670** 0.631 0.489 - 0.813** 
2 (67.4%) 0.417 0.323 - 0.539** 0.529 0.403 - 0.695** (63.4%) 0.433 0.339 - 0.552** 0.546 0.421 - 0.708** 
1 (least affluent)  (66.3%) 0.396 0.305 - 0.515** 0.476 0.361 - 0.628** (62.9%) 0.424 0.330 - 0.544** 0.507 0.389 - 0.661** 
BMI categories           
Normal weight (<25) (74.3%) Ref.  Ref.  (69.4%) Ref.  Ref.  
Overweight (25-29.9) (77.6%) 1.196 0.984 - 1.454 1.251 1.021 - 1.533* (73.6%) 1.226 1.019 - 1.475* 1.277 1.052 - 1.549* 
Class I obesity (30-34.9) (71.1%) 0.851 0.681 - 1.063 0.975 0.771 - 1.232 (69.0%) 0.981 0.791 - 1.217 1.114 0.887 - 1.398 
Class II obesity (35-39.9) (68.4%) 0.749 0.547 - 1.023 0.845 0.607 - 1.177 (65.8%) 0.847 0.624 - 1.151 0.939 0.680 - 1.297 
Class II obesity (>40) (53.5%) 0.399 0.244 - 0.650** 0.473 0.282 - 0.796** (52.1%) 0.479 0.295 - 0.780** 0.562 0.335 - 0.941* 
Coronary heart diseases           
No (74.6%) Ref.  Ref.  (70.9%) Ref.  Ref.  
Yes (67.4%) 0.702 0.527 ± 0.936* 0.968 0.711 - 1.318 (64.4%) 0.740 0.559 ± 0.980* 1.013 0.749 - 1.369 
Depression           
No (74.0%) Ref.  Ref.  (70.5%) Ref.  Ref.  
Yes (75.8%) 1.099 0.801 - 1.509 1.195 0.858 - 1.666 (69.5%) 0.952 0.709 - 1.280 1.007 0.738 - 1.373 
Respiratory  diseases           
No (75.0%) Ref.  Ref.  (71.6%) Ref.  Ref.  
Yes (69.1%) 0.748 0.603 ± 0.927** 0.853 0.681 - 1.069 (63.3%) 0.682 0.555 - 0.838* 0.776 0.625 - 0.963* 
Stroke          
No (74.2%) Ref.  Ref.  (70.6%) Ref.  Ref.  
Yes (71.7%) 0.882 0.565 ± 1.375 1.295 0.812 - 2.066 (66.7%) 0.834 0.545 - 1.275 1.228 0.785 - 1.920 
Diabetes           
No (75.8%) Ref.  Ref.  (72.0%) Ref.  Ref.  
Yes (62.8%) 0.539 0.434 - 0.668** 0.703 0.557 - 0.887** (60.2%) 0.589 0.476 - 0.727** 0.744 0.592 - 0.936* 
N  3270  3270   3270  3270  
R2    0.096     0.102  
* p<0.05; ** p<0.01 BMI= body mass index; CI= confidence interval; CRC= colorectal cancer; OR= odds ratio 
 
